Alterity Therapeutics (ATHE) Interest & Investment Income (2018 - 2019)
Alterity Therapeutics (ATHE) posted quarterly Interest & Investment Income of $9655.5 for Q4 2019, down 79.72% year-over-year from $47609.3 in Q4 2018, and down 79.72% on a QoQ basis from $47609.3 in Q4 2018.
Alterity Therapeutics (ATHE) Interest & Investment Income (2018 - 2019) Analysis & Trends
Alterity Therapeutics (ATHE) has reported Interest & Investment Income for 2 consecutive years, with $9655.5 the latest figure, recorded in Q4 2019.
- In Q4 2019, Interest & Investment Income fell 79.72% year-over-year to $9655.5; the TTM figure through Dec 2019 stood at $465970.4 (changed N/A YoY), while the FY2025 annual figure was $285819.6, up 61.58% from the prior year.
- Interest & Investment Income came in at $9655.5 for Q4 2019 at Alterity Therapeutics, down from $47609.3 in the prior quarter.
- The five-year high for Interest & Investment Income was $47609.3 in Q4 2018, with the low at $9655.5 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 44.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 27.66 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 114.80 Mn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | - |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | - |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 44.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 26.60 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | 19.51 Mn |
| 10 | Alterity Therapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 9,655.51 |
| Dec 31, 2018 | 47,609.30 |